StockNews.com initiated coverage on shares of VBI Vaccines (NASDAQ:VBIV – Free Report) in a research note issued to investors on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
VBI Vaccines Price Performance
Shares of NASDAQ VBIV opened at $0.60 on Friday. The business’s 50 day moving average price is $0.61 and its two-hundred day moving average price is $0.61. The company has a market cap of $17.27 million, a PE ratio of -0.05 and a beta of 1.90. VBI Vaccines has a twelve month low of $0.45 and a twelve month high of $3.47.
VBI Vaccines Company Profile
Featured Stories
- Five stocks we like better than VBI Vaccines
- Profitably Trade Stocks at 52-Week Highs
- Garmin Navigates to New Highs Driven By Wearables Trend
- Retail Stocks Investing, Explained
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- What Investors Need to Know About Upcoming IPOs
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.